SABCS 2017 - Breast Cancer

Dr Hope Rugo addresses some of the main differences between the 3 CDK4/6 inhibitors that are FDA-approved in HR-positive metastatic breast cancer.
Dr Hope Rugo cites that CDK4/6 inhibitors play a critical role in estrogen signaling and can be very effective in treating metastatic breast cancer when used in combination with hormone therapy.
The combination of abemaciclib plus pembrolizumab is safe and effective in women with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer.
The combination of the PD-1 inhibitor pembrolizumab plus either doxorubicin or an aromatase inhibitor may be a feasible approach to treating triple-negative or hormone receptor (HR)-positive metastatic breast cancer.
Abemaciclib demonstrated efficacy and an acceptable safety profile in treating brain metastases in hormone receptor (HR)-positive/HER2-negative breast cancer, but was not effective for brain metastases in HR-positive/HER2-positive breast cancer.
The addition of Ra-223 to hormonal therapy and denosumab is a feasible and safe combination therapy in patients with hormone receptor (HR)-positive breast cancer with bone-dominant metastasis.
The combination of abemaciclib plus endocrine therapy is an effective treatment option in patients with hormone receptor–positive, HER2-negative advanced breast cancer with liver metastases, with significantly higher clinical benefits than those derived from single-agent endocrine therapy.
In a subanalysis of the MONARCH 2 and 3 studies, patients with hormone receptor–positive, HER2-negative breast cancer with poor prognostic factors received greater benefit from the addition of abemaciclib to endocrine therapy than those without a poor prognosis.
The combination of the selective histone deacetylase inhibitor entinostat plus a CDK4/6 inhibitor demonstrates greater synergistic antitumor activity against estrogen receptor (ER)-positive breast cancer and triple-negative (TN) breast cancer than either agent alone.
MonarchE is an ongoing, open-label phase 3 study designed to evaluate invasive disease-free survival in patients with hormone receptor‒positive, HER2-negative advanced breast cancer receiving abemaciclib plus standard-of-care adjuvant endocrine therapy (ET).
Page 3 of 4
Results 21 - 30 of 32